Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Pharmacol Sci. 2005 May;26(5):244-51.

PPARs: therapeutic targets for metabolic disease.

Author information

  • 1Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, USA. joel_berger@merck.com

Abstract

The three peroxisome-proliferator-activated receptor (PPAR) subtypes, PPAR-gamma, PPAR-alpha and PPAR-delta, are nuclear receptors that have been the focus of extensive research during the past decade. These receptors function as lipid sensors that coordinately regulate the expression of large gene arrays and, thereby, modulate important metabolic events. They are also the targets of drugs that are effective in the treatment of metabolic disorders (type 2 diabetes mellitus and atherosclerosis) that afflict industrialized societies at epidemic levels. Ongoing research indicates that modulation of PPAR activity might be an effective therapy for additional maladies associated with the metabolic syndrome, including obesity. Novel PPAR ligands are now being developed that possess broader efficacies and improved tolerability compared with currently available therapeutic agents.

PMID:
15860371
DOI:
10.1016/j.tips.2005.03.003
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center